Interstitial PF Flares in Hospital Stays Seen to Raise Morbidity Risk in Non-IPF Patients, Too

A Mayo Clinic study reported that patients with fibrotic interstitial lung disease are at a threefold higher risk of substantial morbidity when hospitalized for acute lung exacerbations, whether or not they have idiopathic pulmonary fibrosis (IPF). While the frequency and outcomes of acute respiratory exacerbations in IPF patients are rather well-documented, corresponding…

An interaction between cells in the lungs’ vasculature appears to spur tissue regeneration and is a potential target for therapies against fibrosis, according to a study titled “Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis,” published in the journal Nature Medicine. Lungs, as a result of their…

Dr. Ferran Morell Brotad is a pulmonologist who has a particular interests in bronchial asthma, interstitial lung disease, pulmonary fibrosis, and sarcoidosis among others. His interest is also to diagnose the patients who have a lung disease, which sometimes can be really difficult. Watch the video to learn more…

“Bonnie H., 75, a Lung Institute patient, suffers from COPD and pulmonary fibrosis. Bonnie received venous stem cell therapy at the Lung Institute to improve her quality of life and symptoms.” Learn more about Pulmonary Fibrosis: https://bit.ly/1lfMsiZ…

Last week’s hot topic on pulmonary fibrosis was Fibrotic Pathways in IPF May Have a Common Protein and New Treatment Target written by Magdalena Kegel. This article is focused on how a  motor protein called myosin II was identified…

https://www.youtube.com/watch?v=W0sMSK0ej2g “Pulmonary fibrosis affects as many as 14-43 people per 100,000 worldwide. Watch this video to find out more about this patient’s testimony.” Learn more about IPF here: https://bit.ly/1QiRmr3…